Presented by Prof Dr Mariana Brandão (Institut Jules Bordet, Brussels, Belgium) & Prof Dr Anne-Marie Dingemans (Erasmus MC, Rotterdam, The Netherlands)
At the 2026 European Lung Cancer Congress (ELCC), an educational session focused on challenging-to-target oncogenic alterations in non-small cell lung cancer (NSCLC). The session specifically highlighted recent advances in the understanding and management of rare genomic subtypes such as MET exon 14 (METex14) skipping mutations and non-V600 BRAF mutations. In this video, Prof Dr Mariana Brandão, medical oncologist at the Institut Jules Bordet in Brussels and Prof Dr Anne-Marie Dingemans, pulmonologist at the Erasmus MC in Rotterdam discuss some of the key takeaways from this session.
METex14 skipping mutations represent a rare but clinically relevant molecular alteration, occurring in approximately 3% of NSCLC cases. A key takeaway from the session was the critical role of optimized detection techniques. Evidence presented, including data from a large Danish cohort, demonstrated that reliance on DNA-based testing alone may lead to underdetection, potentially missing up to 12% of cases. Consequently, the integration of both DNA- and RNA-based next-generation sequencing (NGS) approaches was strongly advocated to improve diagnostic sensitivity. Such comprehensive testing should be broadly implemented across patient populations, including those with non-squamous histology and those with a history of smoking, as METex14 alterations are not restricted to classical molecular subgroups and may also be enriched in more aggressive histologies such as sarcomatoid carcinomas.
From a therapeutic perspective, MET-targeted tyrosine kinase inhibitors (TKIs), specifically capmatinib and tepotinib, have received regulatory approval in Europe for use in the second-line setting. Clinical evidence supporting these agents is primarily derived from single-arm phase II trials, reflecting the rarity of this molecular subset. Reported objective response rates range from approximately 45% to 50%, with a notable proportion of patients achieving durable responses. Importantly, no robust predictive biomarkers beyond the presence of the METex14 alteration itself have been identified that may facilitate a refined patient selection. Importantly, preliminary data with tepotinib and capmatinib also suggest intracranial activity in patients with brain metastases.
The session also addressed the clinical challenges associated with non-V600 BRAF mutations, which constitute approximately two-thirds of all BRAF-mutated NSCLC cases. Unlike the well-characterized efficacy of BRAF and MEK inhibition in NSCLC patients with a BRAF V600E mutation, the management of class II and class III BRAF mutations remains less clearly defined. However, emerging preclinical and early clinical data suggest that some of these tumors may respond to MEK inhibition, with or without concurrent BRAF inhibition. Additionally, several investigational approaches are under evaluation, including next-generation RAF inhibitors and antibody–drug conjugates, offering potential new therapeutic avenues for this underserved patient population.
Notably, non-V600 BRAF mutations are more frequently associated with a history of smoking and are linked to poorer long-term outcomes compared to V600E-mutant disease. The latter is probably also influenced by a lack of approved targeted therapies for these patients. The session also highlighted the necessity of managing these patients within specialized, high-volume centers where multidisciplinary expertise, including molecular pathology, can guide individualized treatment strategies and facilitate enrollment in clinical trials.
References:
Donderdag 12 november 2026
Kontich
Gent
Linter
Onthaal vanaf 18 uur
Programma van 19 tot 22 uur
Kies jouw locatie en schrijf je in
Donderdag 12 november 2026
Kontich
Gent
Linter
Onthaal vanaf 18 uur
Programma van 19 tot 22 uur
Kies jouw locatie en schrijf je in